徐海波
一、个人简介
徐海波，博士，三级教授，硕博士生导师，英国女王大学肿瘤生物学博士后，英国布里斯托大学分子药理学博士后。现为威尼斯98488药学院中药药理学教研室主任，四川省学术技术带头人后备人选，四川省中医药管理局学术技术带头人，四川省海外高层次留学人才。担任世界中医药学会联合会道地药材多维评价专委会理事，世界中医药学会联合会代谢病专委会理事，中国中西医结合学会活血化瘀专业委员会中药药理专家委员会副主任委员，中华中医药学会中药实验药理分会委员，中国药理学会中药与天然药物药理专委会委员，中国中医药信息学会中药药理分会理事，四川省药理学会理事，四川省药理学会肿瘤药理专委会副主任委员，全国高等中医药院校中药学类专业双语规划教材建设指导委员会委员，Frontiers in Pharmacology和Frontiers in Oncology等SCI期刊编委，Signal Transduction and Targeted Therapy等10多个SCI期刊审稿专家，成都天府海智计划专家，四川欧美同学会第一届理事会理事，四川省第八次归侨侨眷代表大会代表。
主要从事中药抗肿瘤和心血管病的药理研究，主持科研项目近20项，其中国家自然科学基金面上项目2项，部省级项目5项。以第一位置作者、唯一或领头通讯作者在Molecular Cancer、Pharmacology & Therapeutics、Cardiovascular Research等期刊发表SCI论文30余篇（含ESI高被引论文3篇、热点论文2篇、Faculty Opinions优秀论文1篇），编委国外专著《Nitric Oxide: Methods and Protocols》1部，申请国家发明专利2项。曾获欧洲高血压学会的欧洲研究者旅行基金奖1次、英国生理学会旅行基金奖2次、英国心脏基金会旅行基金奖1次、北爱尔兰肿瘤研究学会旅行基金奖1次。
主持四川省教育厅药理学双语教学改革项目，主编全国高等中医药院校中药学类专业双语规划教材《Chinese Medicinal Pharmacology》1部，编委《Pharmacology of Chinese Materia Medica》、《药理学》等国家级教材5部。入选首批国家级一流本科课程1门。
培养四川省优秀博士毕业生2人。
中文邮箱：xuhb@hotmail.com E-mail (English only)：haibo.xu@cdutcm.edu.cn
二、代表性论文
1. Tang S#, Liang Y#, Wang M, Lei J, Peng Y, Tao Q, Ming T, Yang W*, Zhang C, Guo J*, Xu H*. Qinhuo Shanggan oral solution resolves acute lung injury by down-regulating TLR4/NF-κB signaling cascade and inhibiting NLRP3 inflammasome activation. Frontiers in immunology. 2023;14:1285550.
2. Sun Q, Tao Q, Ming T, Tang S, Zhao H, Liu M, Yang H, Ren S, Lei J, Liang Y, Peng Y, Wang M, Xu H*. Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer. Phytomedicine. 2023;114:154792.
3. Zhao H, Tang S, Tao Q, Ming T, Lei J, Liang Y, Peng Y, Wang M, Liu M, Yang H, Ren S, Xu H*. Ursolic Acid Suppresses Colorectal Cancer by Down-Regulation of Wnt/β-Catenin Signaling Pathway Activity. Journal of Agricultural and Food Chemistry. 2023;71(9):3981-3993.
4. Ming T, Tao Q, Tang S, Zhao H, Yang H, Liu M, Ren S, Xu H*. Curcumin: An epigenetic regulator and its application in cancer. Biomedicine & Pharmacotherapy. 2022;156:113956.
5. Ren S, Liu M, Yang H, Zhao H, Tang S, Ming T, Tao Q, Xu H*. Resveratrol suppresses colorectal cancer by down-regulation of Notch signaling pathway activity. Gut. 2022;71(S2):A45-A46.
6. Yang H, Liu M, Ren S, Zhao H, Ming T, Tang S, Tao Q, Xu H*. Inhibition of colorectal cancer by scutellarin via modulation of Hippo signaling pathway activity. Gut. 2022;71(S2):A45.
7. Liu M, Ren S, Yang H, Zhao H, Ming T, Tang S, Tao Q, Xu H*. Baitouweng Decoction ameliorates colitis-associated colorectal cancer by inhibiting Hedgehog signaling cascade. Gut. 2022;71(S2):A41-A42.
8. Zhao H#, Ren S#, Yang H, Tang S, Guo C, Liu M, Tao Q, Ming T, Xu H*. Peppermint essential oil: its phytochemistry, biological activity, pharmacological effect and application. Biomedicine & Pharmacotherapy. 2022;154:113559.
9. Zhao H#, Ming T#, Tang S, Ren S, Yang H, Liu M, Tao Q, Xu H*. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Molecular Cancer. 2022;21(1):144.
10. Chen L#, Liu M#, Yang H, Ren S, Sun Q, Zhao H, Ming T, Tang S, Tao Q, Zeng S, Meng X, Xu H*. Ursolic acid inhibits the activation of smoothened-independent non-canonical hedgehog pathway in colorectal cancer by suppressing AKT signaling cascade. Phytotherapy Research. 2022;36(9):3555-3570.
11. Sun Q, Yang H, Liu M, Ren S, Zhao H, Ming T, Tang S, Tao Q, Chen L, Zeng S, Duan DD*, Xu H*. Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota. Phytomedicine. 2022;103:154227.
12. Zeng S#, Tan L#, Sun Q, Chen L, Zhao H, Liu M, Yang H, Ren S, Ming T, Tang S, Tao Q, Meng X, Xu H*. Suppression of colitis-associated colorectal cancer by scutellarin through inhibiting Hedgehog signaling pathway activity. Phytomedicine. 2022;98:153972.
13. Sun Q#, Gong T#, Liu M, Ren S, Yang H, Zeng S, Zhao H, Chen L, Ming T, Meng X, Xu H*. Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine. 2022;94:153805.
14. Zhao H, Zeng S, Chen L, Sun Q, Liu M, Yang H, Ren S, Ming T, Meng X, Xu H*. Updated pharmacological effects of Lonicerae japonicae flos, with a focus on its potential efficacy on coronavirus disease-2019 (COVID-19). Current Opinion in Pharmacology. 2021;60:200-207.
15. Sun Q, He M, Zhang M, Zeng S, Chen L, Zhao H, Yang H, Liu M, Ren S, Xu H*. Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery. Frontiers in Pharmacology. 2021;12:685002.
16. Zeng S, Chen L, Sun Q, Zhao H, Yang H, Ren S, Liu M, Meng X, Xu H*. Scutellarin ameliorates colitis-associated colorectal cancer by suppressing Wnt/β-catenin signaling cascade. European Journal of Pharmacology. 2021;906:174253.
17. Zhao H, He M, Zhang M, Sun Q, Zeng S, Chen L, Yang H, Liu M, Ren S, Meng X, Xu H*. Colorectal Cancer, Gut Microbiota and Traditional Chinese Medicine: A Systematic Review. American Journal of Chinese Medicine. 2021;49(4):805-828.
18. Chen L#, He M#, Zhang M, Sun Q, Zeng S, Zhao H, Yang H, Liu M, Ren S, Meng X*, Xu H*. The role of non-coding RNAs in colorectal cancer, with a focus on its autophagy. Pharmacology & Therapeutics. 2021;226:107868.
19. Sun Q, He M, Zhang M, Zeng S, Chen L, Zhou L, Xu H*. Ursolic acid: A systematic review of its pharmacology, toxicity and rethink on its pharmacokinetics based on PK-PD model. Fitoterapia. 2020;147:104735.
20. Zhang S, Xu H*, Zhang S*, Li X. Identification of the Active Compounds and Significant Pathways of Artemisia Annua in the Treatment of Non-Small Cell Lung Carcinoma based on Network Pharmacology. Medical Science Monitor. 2020;26:e923624
21. Tan L, Lei N, He M, Zhang M, Sun Q, Zeng S, Chen L, Zhou L, Meng X, Xu H*. Scutellarin protects against human colorectal cancer in vitro by down regulation of hedgehog signaling pathway activity. International Journal of Pharmacology. 2020;16(1):53-62.
22. Wan S, Tan L, Lei N, Shi Y, He M, Zhang M, Zhou L, Jin L, Meng X, Yang K, Xu H*. Compound Bieshe Kang’ai inhibits proliferation and induces apoptosis in HCT116 human colorectal cancer cells. Tropical Journal of Pharmaceutical Research. 2018;17(11):2163-2168.
23. Xu H*, Wang D, Peng C, Huang X, Ou M, Wang N, Wang P, Zhou L, Ye X. Rabbit sera containing compound danshen dripping pill attenuate leukocytes adhesion to TNF-alpha--activated human umbilical vein endothelial cells by suppressing endothelial ICAM-1 and VCAM-1 expression through NF-kappaB signaling pathway. Journal of Cardiovascular Pharmacology. 2014;63(4):323-332.
24. Xu H*, Wu Q, Peng C, Zhou L. Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method. BMC Complementary and Alternative Medicine. 2013;13:239.
25. Cao Y, Liu X, Xu H*. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients. Clinical Laboratory. 2012;58(7-8):845-850.
26. Xu H, Oliveira-Sales EB, McBride F, Liu B, Hewinson J, Toward M, Hendy EB, Graham D, Dominiczak AF, Giannotta M, Waki H, Ascione R, Paton JF#, Kasparov S#*. Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension. Cardiovascular Research. 2012;96(3):552-560.
27. Xu H, Toward M, Paton JF, Kasparov S. Over expressed junctional adhesion molecule-1 is implicated in angiotensin-II induced-hypertension. Journal of Hypertension. 2009;27(S4):S17-S18.
28. Xu H, Posner GH, Stevenson M, Campbell FC*. Apc(MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis. 2010;31(8):1434-1441.
29. Xu H#, McCann M#, Zhang Z, Posner GH, Bingham V, El-Tanani M, Campbell FC. Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Molecular Carcinogenesis. 2009;48(8):758-772.
30. Xu H, El-Tanani M, Campbell FC. Nuclear vitamin D receptor regulation of OPN/TCF4/beta-catenin signalling. European Journal of Cancer. 2005;S3(2):58-58.